News
A new study projects that aligning U.S. cholesterol treatment with clinical guidelines could significantly reduce cardiovascular events nationwide. The study, led by researchers at Baltimore-based ...
Merck faces a looming challenge with the 2028 patent expiration of Keytruda, but it’s not sitting around twiddling test tubes ...
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results